secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2026-05-29T11:40:17+00:00
Accession:  0001171843-26-003778
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose delays Hanmi acquisition closing to June 2026 on pending Korean regulatory approvals
--------------------------------------------------------------------------------

- Closing of plan of arrangement with Hanmi delayed to June 2026 as Korean regulatory approvals remain in progress; parties expect closing to occur.
- Shareholders to receive C$2.41 per share (28% premium over 30-day VWAP on the TSX) upon completion.
- Aptose received additional US$2.0M advance under US$11.9M loan facility from Hanmi, total draws now US$9.9M; final US$2.0M expected shortly.
- Advances support uninterrupted continuation of TUSCANY clinical trial for tuspetinib in frontline AML.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184326003778/0001171843-26-003778-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184326003778/f8k_052926.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-003778

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer